Literature DB >> 19959164

Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus.

Rami J Badreddine1, Ganapathy A Prasad, Kenneth K Wang, Louis M Wong Kee Song, Navtej S Buttar, Kelly T Dunagan, Lori S Lutzke, Lynn S Borkenhagen.   

Abstract

BACKGROUND: The incidence and risk factors for recurrence of dysplasia after ablation of Barrett's esophagus (BE) have not been well defined.
OBJECTIVE: To determine the rate and predictors of dysplasia/neoplasia recurrence after photodynamic therapy (PDT) in BE.
SETTING: Retrospective analysis of a prospective cohort of BE patients seen at a specialized BE unit.
METHODS: Patients underwent a standard protocol assessment with esophagogastroduodenoscopy and 4-quadrant biopsies every centimeter at 3-month intervals after ablation. Recurrence was defined as the appearance of any grade of dysplasia or neoplasia after 2 consecutive endoscopies without dysplasia. Entry histology, demographics, length of BE, presence and length of diaphragmatic hernia, EMR, stricture formation, nonsteroidal anti-inflammatory drug use, smoking, and the presence of nondysplastic BE or squamous epithelium were assessed for univariate associations. Time-to-recurrence analysis was done by using Cox proportional hazards regression. A multivariate model was constructed to establish independent associations with recurrence.
RESULTS: A total of 363 patients underwent PDT with or without EMR. Of these, 261 patients were included in the final analysis (44 lost to follow-up, 46 had residual dysplasia, and 12 had no dysplasia at baseline). Indication for ablation was low-grade dysplasia (53 patients, 20%), high-grade dysplasia (152 patients, 58%), and intramucosal cancer (56 patients, 21%). Median follow-up was 36 months (interquartile range 18-79 months). Recurrence occurred in 45 patients. Median time to recurrence was 17 months (interquartile range 8-45 months). Significant predictors of recurrence on the multivariate model were older age (hazard ratio [HR] 1.04, P=.029), presence of residual nondysplastic BE (HR 2.88, P=.012), and a history of smoking (HR 2.68, P=.048). LIMITATIONS: Possibility of missing prevalent dysplasia despite aggressive surveillance.
CONCLUSION: Recurrence of dysplasia/neoplasia after PDT ablation is associated with advanced age, smoking, and residual BE. Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19959164      PMCID: PMC2981349          DOI: 10.1016/j.gie.2009.08.031

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  35 in total

1.  Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole.

Authors:  H Schulz; S Miehlke; D Antos; K U Schentke; M Vieth; M Stolte; E Bayerdörffer
Journal:  Gastrointest Endosc       Date:  2000-06       Impact factor: 9.427

Review 2.  Photodynamic therapy of Barrett's esophagus.

Authors:  K K Wang
Journal:  Gastrointest Endosc Clin N Am       Date:  2000-07

3.  Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study.

Authors:  R E Sampliner; D Faigel; M B Fennerty; D Lieberman; A Ippoliti; K Lewin; W M Weinstein
Journal:  Gastrointest Endosc       Date:  2001-05       Impact factor: 9.427

4.  Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy.

Authors:  K K Krishnadath; K K Wang; K Taniguchi; T J Sebo; N S Buttar; M A Anderson; L S Lutzke; W Liu
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

5.  High power setting argon plasma coagulation for the eradication of Barrett's esophagus.

Authors:  J C Pereira-Lima; J V Busnello; C Saul; E B Toneloto; C V Lopes; C B Rynkowski; C Blaya
Journal:  Am J Gastroenterol       Date:  2000-07       Impact factor: 10.864

6.  Buried dysplasia and early adenocarcinoma arising in barrett esophagus after porfimer-photodynamic therapy.

Authors:  Mari Mino-Kenudson; Shinichi Ban; Masaya Ohana; William Puricelli; Vikram Deshpande; Michio Shimizu; Norman S Nishioka; Gregory Y Lauwers
Journal:  Am J Surg Pathol       Date:  2007-03       Impact factor: 6.394

7.  Risk factors for Barrett's esophagus: a case-control study.

Authors:  Massimo Conio; Rosangela Filiberti; Sabrina Blanchi; Roberto Ferraris; Santino Marchi; Paolo Ravelli; Gabriella Lapertosa; Gaetano Iaquinto; Renato Sablich; Riccardo Gusmaroli; Hugo Aste; Attilio Giacosa
Journal:  Int J Cancer       Date:  2002-01-10       Impact factor: 7.396

8.  Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia.

Authors:  Mary P Bronner; Bergein F Overholt; Shari L Taylor; Rodger C Haggitt; Kenneth K Wang; J Steven Burdick; Charles J Lightdale; Michael Kimmey; Hector R Nava; Michael V Sivak; Norman Nishioka; Hugh Barr; Marcia I Canto; Norman Marcon; Marcos Pedrosa; Michael Grace; Michelle Depot
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

9.  Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

Authors:  Lesley A Anderson; R G Peter Watson; Seamus J Murphy; Brian T Johnston; Harry Comber; Jim Mc Guigan; John V Reynolds; Liam J Murray
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

View more
  21 in total

1.  Sixteen-year follow-up of Barrett's esophagus, endoscopically treated with argon plasma coagulation.

Authors:  Mariana Milashka; Annabelle Calomme; Jean Luc Van Laethem; Daniel Blero; Pierre Eisendrath; Olivier Le Moine; Jacques Devière
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

2.  Medical and endoscopic management of high-grade dysplasia in Barrett's esophagus.

Authors:  K K Wang; J M Tian; E Gorospe; J Penfield; G Prasad; T Goddard; M Wongkeesong; N S Buttar; L Lutzke; S Krishnadath
Journal:  Dis Esophagus       Date:  2012-03-12       Impact factor: 3.429

Review 3.  Review: Experimental models for Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Katherine S Garman; Roy C Orlando; Xiaoxin Chen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

4.  Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process.

Authors:  Cathy Bennett; Nimish Vakil; Jacques Bergman; Rebecca Harrison; Robert Odze; Michael Vieth; Scott Sanders; Laura Gay; Oliver Pech; Gaius Longcroft-Wheaton; Yvonne Romero; John Inadomi; Jan Tack; Douglas A Corley; Hendrik Manner; Susi Green; David Al Dulaimi; Haythem Ali; Bill Allum; Mark Anderson; Howard Curtis; Gary Falk; M Brian Fennerty; Grant Fullarton; Kausilia Krishnadath; Stephen J Meltzer; David Armstrong; Robert Ganz; Gianpaolo Cengia; James J Going; John Goldblum; Charles Gordon; Heike Grabsch; Chris Haigh; Michio Hongo; David Johnston; Ricky Forbes-Young; Elaine Kay; Philip Kaye; Toni Lerut; Laurence B Lovat; Lars Lundell; Philip Mairs; Tadakuza Shimoda; Stuart Spechler; Stephen Sontag; Peter Malfertheiner; Iain Murray; Manoj Nanji; David Poller; Krish Ragunath; Jaroslaw Regula; Renzo Cestari; Neil Shepherd; Rajvinder Singh; Hubert J Stein; Nicholas J Talley; Jean-Paul Galmiche; Tony C K Tham; Peter Watson; Lisa Yerian; Massimo Rugge; Thomas W Rice; John Hart; Stuart Gittens; David Hewin; Juergen Hochberger; Peter Kahrilas; Sean Preston; Richard Sampliner; Prateek Sharma; Robert Stuart; Kenneth Wang; Irving Waxman; Chris Abley; Duncan Loft; Ian Penman; Nicholas J Shaheen; Amitabh Chak; Gareth Davies; Lorna Dunn; Yngve Falck-Ytter; John Decaestecker; Pradeep Bhandari; Christian Ell; S Michael Griffin; Stephen Attwood; Hugh Barr; John Allen; Mark K Ferguson; Paul Moayyedi; Janusz A Z Jankowski
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

5.  Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus.

Authors:  Kazuhiro Yasuda; Sung Eun Choi; Norman S Nishioka; David W Rattner; William P Puricelli; Angela C Tramontano; Seigo Kitano; Chin Hur
Journal:  Dig Dis Sci       Date:  2014-01-07       Impact factor: 3.199

6.  Endoscopic management of early esophageal neoplasia: an emerging standard.

Authors:  Kelly M Galey; Candice L Wilshire; Thomas J Watson; Marabel D Schneider; Vivek Kaul; Carolyn E Jones; Virginia R Litle; Asad Ullah; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2011-08-03       Impact factor: 3.452

Review 7.  Ablative therapies for Barrett's esophagus.

Authors:  Katherine S Garman; Nicholas J Shaheen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

Review 8.  Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma.

Authors:  Cadman L Leggett; Emmanuel C Gorospe; Kenneth K Wang
Journal:  Gastroenterol Clin North Am       Date:  2013-03       Impact factor: 3.806

9.  Ablation is in the eye of the beholder.

Authors:  Kenneth K Wang
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

10.  A submucosal tumor-like recurrence of early esophageal cancer after endoscopic submucosal dissection.

Authors:  Jeong Cheon Choi; Gwang Ha Kim; Do Youn Park; Hyeog Gyu Seoung; Yong Jae Lee; Ji Hye Kim; Tae Kyun Kim; Hoseok I
Journal:  Clin Endosc       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.